 MALVERN, Pa., May 28, 2021 GLOBE NEWSWIRE -- Baudax Bio, Inc. NASDAQ:BXRX the Company, a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that it has determined to withdraw from shareholder consideration Proposal 3 set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on March 11, 2021, with respect to an increase in the number of shares of common stock authorized for issuance under the Companys Amended and Restated Certificate of Incorporation. As a result, the Company has determined to cancel the reconvening of its annual meeting of shareholders for the consideration of Proposal 3, which was previously adjourned solely with respect to Proposal 3 to 10:00 a.m. Eastern Time on June 3, 2021. All other items set forth in the Companys Definitive Proxy Statement were submitted to shareholder vote at the Companys annual meeting of shareholders on April 7, 2021. 